 | | Vol. 15.49 – 14 December, 2023 |
| |
|
|
| Scientists derived a dormancy-associated residual tumor cell signature that mirrored the transcriptional response to neoadjuvant therapy in patients and was enriched for extracellular matrix-related pathways.
[Cancer Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators analyzed whether depletion of Munc18-1 interacting protein 3 (Mint3), which activated hypoxia-inducible factor 1 during normoxia, sensitized TNBC to chemotherapy.
[Cell Death & Disease] |
|
|
|
| Researchers demonstrated that the expression of Sine oculis homeobox homolog 1 (SIX1) varied among different subtypes of breast cancer and that it upregulated breast cancer grading and lymph node metastasis.
[Journal of Translational Medicine] |
|
|
|
| Scientists highlighted patatin-like phospholipase domain-containing lipase 8 (PNPLA8) as key regulator of phospholipid metabolic reprogramming and malignant phenotypes in TNBC.
[Breast Cancer Research] |
|
|
|
| Researchers reported the development of a selectable system to quantify genome mutation and demonstrated its utility by comparing the mutagenic activities of three leading candidates—APOBEC3A, APOBEC3B, and APOBEC3H.
[PLOS Genetics] |
|
|
|
| The authors designed a very simple, biocompatible, and non-toxic amine-capped ZnO quantum dots to overcome the Methotrexate resistance on the MDA-MB-231 breast cancer cell line.
[Scientific Reports] |
|
|
|
| Investigators assessed the impact of a Ketogenic diets on growth and metastasis of triple negative murine 4T1 mammary tumors, and on the progression of luminal breast tumors in an autochthonous MMTV-PyMT mouse model.
[Clinical & Experimental Metastasis] |
|
|
|
| Tumors were induced via a single intraperitoneal injection of 7,12-Dimethlbenzanthraceneat a dose of 80 mg/kg body weight to the test rats and allowed to develop for about four months.
[Heliyon] |
|
|
|
| Researchers observed that 3, 3′-Diindolylmethane-coated nanopatticles (DIM-NPs) had an average diameter of 102.3 nm and a PDI of 0.182. When treated with DIM-NPs for 48 hours, both MCF7 and MDA-MB-231 cells displayed cytotoxicity at a concentration of 6.25 g/mL compared to untreated cells.
[Heliyon] |
|
|
|
|
| Scientists describe the rationale for targeting CDK4/6 in patients with breast cancer, including a summary of updated clinical evidence and how this should inform clinical practice.
[Nature Reviews Clinical Oncology] |
|
|
|
|
| Breast Cancer Canada announced a new partnership with McPeak-Sirois Group for Clinical Research in Breast Cancer, one of the largest breast cancer clinical research consortiums in Canada, to expand access to clinical research in breast cancer throughout Quebec.
[Financial Post] |
|
|
|
|
| February 14 – 18, 2024
Cancun, Mexico |
|
|
|
|
|
| | University of Amsterdam – Amsterdam, Netherlands |
|
|
|
| | International Iberian Nanotechnology Laboratory – Braga, Portugal |
|
|
|
| | University of Melbourne – Melbourne, Australia |
|
|
|
| | Zhejiang Chinese Medical University – Hangzhou, China |
|
|
|
| | BC Cancer – Vancouver, British Columbia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
